Celcuity shares fall on breast cancer drug delay

Celcuity shares fell after a launch delay overshadowed US approval for the breast cancer drug. The FDA approved the therapy, but a later-than-expected commercial rollout disappointed investors. The stock decline reflects market focus on the timing setback rather than the regulatory milestone.